Last updated on October 2008

Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms

Brief description of study

Stable heart transplant patients on Mycophenolate Mofetil (MMF) will sign a screening consent form in order to be evaluated with the gastrointestinal symptom rating scale (GSRS) questionnaire. Those who score three or more on at least two questions are eligible for the study. Once they sign a study consent they are randomized to one of two arms. It is thought that the severity of GI side effects will be reduced over time in patients who are in the Myfortic arm versus the severity of GI side effects over time in patients who remain on MMF treatment. Patients are evaluated by GSRS, The Psychological Well-Being Schedule, and the IT01/02 Checklist for the evaluation of GI symptoms and followed for one year (visits 1 month, 3 months, 6 months, 12 months).

Clinical Study Identifier: NCT00468936

Contact Investigators or Research Sites near you

Start Over

Nadia Giannetti

McGill University Health Centre
Montreal, QC Canada
  Connect »